FULC
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC) has 2 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 15, 2026.
The most active filer is 10% Owner TANG KEVIN with 3 filings. Insiders have net bought $825K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Alexander C. Sapir
- Employees:55
- HQ:Cambridge, MA, US
- IPO:2019-07-18
Insider Buying
$891K
reported purchases (SEC code P)
Insider Selling
$66K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$237.2M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| 10% Owner | Purchase | 12,966 | $46K | Jul 15 | SEC ↗ | |
| 10% Owner | Purchase | 129,603 | $463K | Jul 15 | SEC ↗ | |
| 10% Owner | Purchase | 107,377 | $382K | Jul 15 | SEC ↗ | |
Ezekowitz AlanFirst filing | Director | Sale | 18,000 | $66K | Jun 30 | SEC ↗ |
Related companies
Fulcrum Therapeutics, Inc. is in the Healthcare sector.